TP53 and ovarian serous carcinoma: Further, in astoundingly clinical genomics studies of high-grade serous ovarian carcinomas (HGSCs), it has been observed that in more than 96% of ovarian cancer patients TP53 is somatically mutated, which derives neoplasm in ovarian tumorigenesis [46,47].